Correction: Trials 15, 160 (2014)
https://doi.org/10.1186/1745-6215-15-160
Following publication of the original article [1], an error was identified between the primary outcome specified in the original protocol, the detailed SAP, and the endpoint forms and a later version of the protocol that this paper was based upon.
The following paragraph in the “Outcomes” section should be changed as follows:
Outcomes
Primary endpoint
Time from randomisation until the first occurring of death or hospitalisation for heart disease (coronary heart disease, arrhythmia, atrial fibrillation, sudden death, resuscitated sudden death), stroke, transient ischaemic attack, peripheral arterial disease or heart failure or first onset of any condition listed above not present at baseline. Primary endpoints will be adjudicated by an independent endpoints committee blinded to treatment arm.
Existing Text:
Outcomes
Primary endpoint
Time from randomisation until the first occurring death, first onset, or hospitalisation for heart disease (coronary heart disease, arrhythmia, new onset/first recorded atrial fibrillation, sudden death, failed sudden death), stroke, or heart failure. Primary endpoints will be adjudicated by an independent Endpoint Committee blinded to the treatment arm.
Reference
Hill NR, Lasserson D, Thompson B, et al. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials. 2014;15:160. https://doi.org/10.1186/1745-6215-15-160.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Hill, N.R., Lasserson, D., Thompson, B. et al. Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials 23, 999 (2022). https://doi.org/10.1186/s13063-022-06972-9
Published:
DOI: https://doi.org/10.1186/s13063-022-06972-9